{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333834","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2026-08-05T11:10:14+00:00","discovered_at":"2026-08-05T11:15:00.352930+00:00","generated_at":"2026-08-05T11:15:29.280560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kymera Q2 net loss narrows to $61.2M; KT-621 AD trial data accelerated to year-end 2026","bullets":["Net loss of $61.2M vs $76.6M in Q2 2025; collaboration revenue of $65.0M from Gilead ($45M) and Sanofi ($20M) milestones.","Cash of $1.5B as of June 30, 2026, providing runway into 2029.","KT-621 Phase 2b AD trial enrollment completed ~6 months early; topline data now expected by year-end 2026 (vs mid-2027).","KT-579 Phase 1 healthy volunteer data expected 4Q26; lupus proof-of-concept trial planned.","Appointed Felix Baker as Chairman, Terence Rooney as CMO; Sanofi initiated KT-485 Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333834","json":"https://secwatch.observer/filing/0001193125-26-333834.json","markdown":"https://secwatch.observer/filing/0001193125-26-333834.md","text":"https://secwatch.observer/filing/0001193125-26-333834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/0001193125-26-333834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:15:29.280560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}